Beam Therapeutics BEAM
Valuation
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 15th percentile, 5-year average -15.1x
Below its usual level · 34th percentile, 5-year average 3.1x
#3456 of 5330 stocks by PB (1 = cheapest)
Below its usual level · 21st percentile, 5-year average 384.8x
#4674 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 2.48 | – | 3.10 | 34% (cheaper than usual) | #3456 of 5330 (1 = cheapest) |
| PE | -25.94 | -4.37 | -15.08 | 15% (cheaper than usual) | – |
| PS | 16.11 | 121.14 | 384.79 | 21% (cheaper than usual) | #4674 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on BEAM.
Sign in to join the discussion.